Thailand Infectious Disease Therapeutics Market Report 2022 to 2030

Thailand Infectious Disease Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Thailand infectious disease therapeutics market will reach a value of $207.56 Mn from $143.84 Mn in 2022, growing at a CAGR of 4.7% during 2022-2030. Infectious Disease Therapeutics in Thailand is dominated by a few domestic pharmaceutical companies such as Siam Bioscience, BioNet-Asia and GPO. The Infectious Disease Therapeutics market in Thailand is segmented into different therapeutic areas and different diseases type. The major factors affecting the Thailand infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious disease treatment in various areas of Thailand.

ID: IN10THPH038 CATEGORY: Pharmaceuticals GEOGRAPHY: Thailand AUTHOR: Dr. Vishwa Modhia

Buy Now

Thailand Infectious Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Thailand infectious disease therapeutics market will reach a value of $207.56 Mn from $143.84 Mn in 2022, growing at a CAGR of 4.7% during 2022-2030.

Thailand is an upper middle-income developing country located in Southeastern Asia bordering the Andaman Sea and the Gulf of Thailand. Thailand, according to the World Factbook, is particularly susceptible to infectious diseases. Food or waterborne infections include bacterial diarrhoea, hepatitis A, and typhoid fever. Dengue fever, Japanese encephalitis, and malaria are all common vector-borne diseases in Thailand. Infections caused by female genital mutilation are also widespread in Thailand and are classified as Type IV by the WHO. Thailand has a significant and rising pharmaceutical market in terms of medicine consumption.

According to a Thailand Board of Investment report, the Thai pharmaceutical market is expected to be worth $7.2 Bn in 2020, with medications for infectious diseases being one of the most important therapeutic categories. Thailand's government spends 4.4% of its GDP on healthcare.

Thailand Infectious Disease Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers Analysis

Thailand has seen numerous advances in infectious illness therapies in recent years. For example, with the advent of new medications such as bedaquiline and delamanid, the country has achieved great advances in the treatment of tuberculosis. Thailand has also been attempting to eradicate malaria by expanding access to diagnostic equipment and developing new treatments. Thailand has long coasts and is close to fast-growing Asian markets, making it a regional centre. These aspects could boost Thailand's infectious disease therapeutics market.

Market Restraints

The creation of novel pharmaceuticals and treatments necessitates substantial investment, and finance can be a barrier for many research efforts. Due to fiscal restrictions or conflicting objectives, funding for research and development in Thailand may be constrained. In Thailand, infectious diseases such as dengue fever, TB, and HIV/AIDS are prevalent. This heavy load can make developing effective therapies and conducting clinical trials difficult. Thailand's high corruption perception and big informal sector pose a risk to enterprises. These factors may deter new entrants into the Thailand infectious disease therapeutics market.

Competitive Landscape

Key Players

Government Pharmaceutical Organization (GPO) - The GPO is a state-owned pharmaceutical company in Thailand that is involved in the development and production of drugs, vaccines, and medical supplies for infectious diseases such as HIV/AIDS, malaria, and tuberculosis
Siam Bioscience - Siam Bioscience is a Thai biopharmaceutical company that develops and produces vaccines and biologics for infectious diseases, including COVID-19. The company has also been involved in the production of diagnostic tests and other medical products
BioNet-Asia - BioNet-Asia is a Thai biopharmaceutical company that specializes in the development and production of vaccines for infectious diseases such as dengue fever, influenza, and hepatitis B. The company has also been involved in the development of COVID-19 vaccines
Chulabhorn Royal Academy (CRA) - The institution collaborates with international organizations in the development of vaccines and therapeutics

Recent Notable Updates

December 2022: Pharmaniaga LifeScience, a wholly-owned subsidiary of Malaysia's premier pharmaceutical business, Pharmaniaga Berhad (Pharmaniaga), has agreed to collaborate on the development of a 6-in-1 Hexavalent Vaccine with BioNet-Asia. The vaccine will give Malaysian healthcare practitioners the finest alternative for immunising children against six deadly childhood diseases.

Healthcare Policies and Reimbursement Scenarios

The Thai Food and Drug Administration is in charge of the regulation of infectious illness medicines in Thailand (TFDA). The TFDA is in charge of assessing the safety, efficacy, and quality of all medications and medical devices, including those used to treat infectious diseases. In terms of reimbursement, Thailand has a mixed healthcare system that includes both public and private providers. Through the National Health Security Office, the government offers subsidised healthcare services to the people, including treatments for infectious diseases (NHSO).

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Infectious Disease Therapeutics Segmentation

By Mode of Treatment (Revenue, USD Billion):

Vaccines
Drugs

By Applications (Revenue, USD Billion):

HIV/AIDS
Influenza
Hepatitis
Malaria
Tuberculosis
Others

By Disease Type (Revenue, USD Billion):

Viral Diseases
Bacterial Diseases
Fungal Diseases
Parasitic Diseases
Others

By Target Organism (Revenue, USD Billion):

Antibiotics
Antivirals
Antifungals
Anti-Parasitic
Others

By End User (Revenue, USD Billion):

Hospitals and Clinics
Ambulatory Care Centers
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.